Skeletal Microstructure in Addison's Disease

Area of Science:

• Endocrinology
• Bone Metabolism
• Medical Imaging

Background:

• Addison's disease (AD) involves deficient adrenal glucocorticoid (GC) production, necessitating GC replacement therapy.
• High-dose GC treatment can lead to adverse effects, and bone mineral density (BMD) data in AD patients are conflicting.
• High-resolution peripheral quantitative computed tomography (HRpQCT) offers detailed assessment of bone microarchitecture and mechanical properties, but has not been used in AD.

Purpose of the Study:

• To evaluate bone health in Addison's disease patients using HRpQCT.
• To compare bone quality and microarchitecture between AD patients on GC therapy and healthy controls.
• To investigate potential correlations between lean mass, GC dose, and skeletal parameters in AD.

Main Methods:

• A cross-sectional study comparing 19 AD patients on GC therapy with 38 matched controls.
• Utilized dual-energy x-ray absorptiometry and HRpQCT to measure volumetric BMD, microarchitecture, and mechanical properties of the tibia and radius.
• Analyzed differences in bone parameters and correlations between lean mass, cumulative GC dose, and bone health outcomes.

Main Results:

• AD patients showed significantly lower lean mass and BMD compared to controls.
• HRpQCT revealed reduced trabecular bone number and volumetric BMD, increased trabecular separation, and diminished cortical bone dimensions at the tibia.
• Tibial stiffness was 21% lower in AD patients, with correlations observed between lean mass and stiffness, and cumulative GC dose and spine BMD.

Conclusions:

• This is the first study to use HRpQCT to assess bone quality in AD patients on GC therapy.
• Findings indicate that AD patients experience loss of lean mass and skeletal fragility, predominantly affecting the tibia's trabecular compartment.
• Bone loss in AD may be linked to both reduced lean mass and the effects of GC treatment.